Company / EPS (Diluted)
AXIM BIOTECHNOLOGIES, INC. EPS (Diluted) History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.04
FY2023
5-year range
-$0.27 / $0.12
FY2019-FY2023
Trend
-133.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-0.08 to $-0.04 over the past 5 years.
Based on SEC 10-K filings.
-0.04 in FY2023.
Improved from $-0.08 to $-0.04 over the past 5 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, eps (diluted) decreased 133.3% year-over-year.
- Peak eps (diluted) was recorded in FY2022.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$0.04 | -133.3% |
| FY2022 | $0.12 | +250.0% |
| FY2018 | -$0.08 | +52.9% |
| FY2017 | -$0.17 | +37.0% |
| FY2016 | -$0.27 | -1250.0% |
| FY2015 | -$0.02 | - |
| FY2013 | - | - |
| FY2012 | - | - |
| FY2011 | $0.00 | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026